SecBot SecBot
SECBOTREPLAY Home › Report › TECH

TECH · Bio-Techne (TECH) filed a preliminary proxy statement (PREM14A) for a…

BIO-TECHNE Corp · PREM14A filed Aug 10, 2026 at 16:34 ET

At the news

BULLISHIMPACT 7/10

PREM14A filed Aug 10, 2026 at 16:34 ET

Bio-Techne (TECH) filed a preliminary proxy statement (PREM14A) for a special shareholder meeting to vote on its acquisition by Merck KGaA (Parent) for $73.00 per share in cash, a 24% premium over the $58.88 closing price on June 24, 2026. The all-cash deal values Bio-Techne at an implied total enterprise value of approximately $11.3 billion. The Board unanimously recommends approval, and Goldman Sachs rendered a fairness opinion. The merger is expected to close by late 2026 or early 2027, subject to shareholder and regulatory approvals, with no financing condition for Parent.

  • Bio-Techne to be acquired by Merck KGaA for $73.00 per share in cash.
  • Merger consideration represents a 24% premium over the $58.88 closing price on June 24, 2026.
  • Implied total enterprise value of approximately $11.3 billion.
  • Board unanimously recommends shareholders vote FOR the merger.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access